SciNeuro Pharmaceuticals: Comprehensive Company Profile

Background

SciNeuro Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to developing innovative treatments for central nervous system (CNS) diseases. Established in December 2020, the company operates with corporate and research facilities in both the United States and China. SciNeuro's mission is to translate scientific discoveries into groundbreaking therapies that restore the joy in living for patients worldwide.

Key Strategic Focus

SciNeuro concentrates on targets supported by human biology that play critical roles in foundational biological processes, aiming to enhance the probability of success in clinical development. The company's strategic focus includes:

• Neurodegenerative Diseases: Developing therapies for conditions such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).

• Innovative Therapeutics: Utilizing advanced technologies, including antisense oligonucleotides (ASOs) and monoclonal antibodies, to address previously undruggable targets.

• Global Partnerships: Collaborating with leading pharmaceutical and biotechnology companies to leverage complementary expertise and accelerate the development of novel therapies.

Financials and Funding

In December 2020, SciNeuro secured a $100 million Series A financing round co-led by Lilly Asia Ventures Fund and Arch Venture Partners. Additional investors included Boyu Capital, General Atlantic, Sequoia Capital China, TF Capital, and Zoo Capital. The funding is allocated to building and advancing a CNS product portfolio, with an initial focus on the Greater China region.

Pipeline Development

SciNeuro has established a robust pipeline of novel therapeutic candidates targeting various CNS diseases. Key pipeline candidates include:

• SNP614: An antisense oligonucleotide targeting leucine-rich repeat kinase 2 (LRRK2), associated with increased risk for Parkinson's disease. SNP614 aims to downregulate LRRK2 mRNA, potentially offering a disease-modifying therapy superior to current symptomatic treatments.

• SNP210: A human autoantibody targeting cytoplasmic TDP-43 aggregates, implicated in neurodegeneration. SNP210 is being developed for amyotrophic lateral sclerosis (ALS) and certain forms of frontotemporal dementia (FTD).

• SNP201: A high-affinity alpha-synuclein antibody designed to bind preferentially to aggregated forms of alpha-synuclein, a major component of Lewy bodies in synucleinopathies such as Parkinson's disease, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). SNP201 aims to achieve better clinical efficacy through superior binding affinity and epitope recognition.

Technological Platform and Innovation

SciNeuro leverages advanced technological platforms and innovative approaches to develop therapies for CNS diseases:

• Antisense Oligonucleotides (ASOs): Utilizing chemically modified ASOs to downregulate target mRNA, as exemplified by SNP614 targeting LRRK2 in Parkinson's disease.

• Monoclonal Antibodies: Developing high-affinity antibodies like SNP201 and SNP210 to target pathogenic protein aggregates in neurodegenerative diseases.

• Collaborative Platforms: Partnering with companies such as Alamar Biosciences to utilize the Attobody™ platform for discovering novel therapeutic antibodies for CNS diseases.

Leadership Team

SciNeuro's leadership comprises experienced professionals with extensive backgrounds in neuroscience and pharmaceutical development:

• Min Li, Ph.D.: Founder and CEO. Former professor at Johns Hopkins Medicine, Senior Vice President and Global Head of Neurosciences R&D at GlaxoSmithKline, and Venture Partner at Lilly Asia Ventures.

• Qiuqing Ang, M.D., Ph.D.: Chief Medical Officer. Over 15 years of leadership positions at Eli Lilly, Pfizer, and GSK for CNS clinical development. Former Chief Scientific Officer at Klus Pharma.

• Danny Chen, Ph.D.: Senior Vice President & Head of Translational Science. Former Executive Director at Pfizer Neuroscience R&D, leading multiple early clinical development programs addressing CNS diseases.

• Paul Stead, Ph.D., MBA: Chief Business Officer. Over 15 years of business development experience within biotech and large pharma, including roles at Adaptimmune Therapeutics, Inovio Pharmaceuticals, Nimbus Therapeutics, and GlaxoSmithKline.

Competitor Profile

Market Insights and Dynamics

The global CNS therapeutics market is experiencing significant growth, driven by an aging population and increasing prevalence of neurodegenerative diseases. Advancements in understanding disease mechanisms and the development of targeted therapies are contributing to this expansion.

Competitor Analysis

Key competitors in the CNS therapeutics space include:

• Biogen: Focuses on neurodegenerative diseases with products like aducanumab for Alzheimer's disease.

• Roche: Develops therapies for CNS disorders, including multiple sclerosis and Alzheimer's disease.

• Eli Lilly: Engages in CNS research with a portfolio targeting Alzheimer's disease and other neurological conditions.

• Novartis: Offers treatments for multiple sclerosis and invests in innovative CNS therapies.